Kumovis to show new end-to-end workflow for medical 3D printing

21.10.2021

  • The highlight is a new end-to-end workflow that enables medtech companies and hospitals to manufacture products from high-performance polymers such as PEEK and bring them to market more quickly in accordance with FDA and MDR criteria.
  • This November, Munich-based start-up Kumovis will be presenting new developments at AM Medical Days, COMPAMED and Formnext in Germany.
  • In addition to the Kumovis R1 3D printer, which will manufacture implants live at the company's Formnext booth, panels and presentations are also part of the program.
Munich, October 21, 2021Kumovis, the Munich-based medical 3D printing start-up, will show its new end-to-end workflow for the additive manufacturing of medical products this fall. With the industry-specific development, Kumovis enables medical devices made of high-performance polymers such as PEEK to be manufactured more efficiently than with conventional processes. What is more, manufacturers can bring these products to market in accordance with FDA and MDR criteria using the Kumovis workflow. Besides exhibiting the Kumovis R1 3D printer and medical applications at its booths, Kumovis will also be represented in panels and presentations at this year’s editions of COMPAMED, Formnext and AM Medical Days.

AM Medical Days: Experience medtech future today

The latter is the new decision-makers and experts conference on all things medical 3D printing at the Estrel Congress Center in Berlin. “As a founding partner of AM Medical Days, Kumovis is proud to be able to make another contribution to the future of 3D printing in medicine today,” says Stefan Leonhardt, co-CEO and co-founder of Kumovis. “Anyone who is professionally involved with 3D-printed medical devices or the future in the operating room shouldn’t miss this event.” Topics like these will be the focus of the panel discussion with Kumovis on the first day of the two-day conference. “Beyond AM Medical Days, we are looking forward to finally getting in touch with people in person again at the two must-attend events COMPAMED and Formnext,” Stefan Leonhardt adds.

Furthermore, he will speak about the current state of 3D-printed polymer implants in his lecture at AM Medical Days: Which applications are possible today, which are still in the development phase? And how can innovations be implemented using 3D printing under more difficult market conditions – MDR is the catchword? Kumovis will answer these and other questions during AM Medical Days. From November 22 to 23, visitors will also find representative 3D-printed build parts made of medical-grade polymers at the Kumovis booth.

Formnext: Additive manufacturing of implants live

The Kumovis team will exhibit its new developments in Frankfurt too. At the start-up’s Formnext booth, Kumovis R1, the FLM 3D printer built for medical manufacturing, can be assessed live at an event for the first time since 2019. This year, Kumovis plans to 3D print implants on site so that every visitor will be able to convince themselves of the part quality.

As at the other two events in November, visitors to the Kumovis booth at Formnext will learn everything about the new end-to-end workflow – from DICOM processing, 3D printing and post-processing to the approval of a medical device. On the one hand, the solution includes the provision of the 3D printer and slicing software; on the other hand, Kumovis provides application-specific processes and regulatory data such as machine qualification and biological and mechanical validation. With this complete package, medical device manufacturers can save costs and serve MDR and FDA markets compliantly and faster than with conventional processes such as milling or injection molding. Kumovis will be at Formnext from November 16 to 19 in hall 12.1, booth E29.

COMPAMED: Approval is focus

Medtech companies and hospitals achieve the familiar mechanical properties from conventional manufacturing when 3D printing medical products with Kumovis R1 and materials such as PEEK, PEKK or PPSU. Like visitors to Formnext, those at COMPAMED in Duesseldorf will be able to get their hands on 3D-printed parts at the Kumovis booth and see the parts’ quality for themselves from November 15 to 18. Application-specific products will be available at the Kumovis booth. And another medical technology concern is on the agenda: the new regulatory requirements of the MDR.

Kumovis will address this topic in the “COMPAMED Suppliers Forum by DeviceMed” and give a presentation under the title “Implants and instruments individualized or mass-produced from high-performance polymers – design, 3D printing and approval”. The Kumovis medical and polymer technology experts will be available for further questions and discussions in hall 13, booth D32.

 

Brief overview of where to meet Kumovis

  • COMPAMED starting November 15; hall 13, booth D32, Messe Duesseldorf
  • Formnext starting November 16; hall 12.1, booth E29, Messe Frankfurt
  • AM Medical Days starting November 22; booth 04, Estrel Congress Center Berlin
 

Media contact

Stefan Killer
Marketing & Communications Manager
Phone: +49 89 61421614
Email: stefan.killer@kumovis.com

 

About Kumovis

One thing up front: Kumovis is more than just another 3D printer manufacturer. Since its founding in 2017, the Munich-based start-up has been working on industry-specific end-to-end workflows to transform the manufacturing of medical devices and thus improve patient care. Kumovis has developed 3D printing technology specifically for this purpose and combined it with clean room technology. Be it in the industrial or surgical environment, the focus is on the economical production of functionalized as well as patient-matched implants and instruments made of high-performance polymers. Kumovis also provides medtech companies and hospitals with a regulatory roadmap and documentation, enabling new medical devices to benefit patients faster.

For more information, please visit www.kumovis.com.

Diesen Artikel teilen

Gallerie

Ähnliche Themen

PHABIOC GmbH startet Serienfertigung der revolutionären SpecPlate für die Pharma- und Biotechforschung

15.10.2024

Die PHABIOC GmbH gibt den Start der Serienfertigung ihrer innovativen SpecPlate bekannt – einer Multiwellplatte, die ...

Weiterlesen

Gute Datenlage: immatics kann direkt in Phase III gehen

10.10.2024

Transkript berichtet über das Tübinger Healthcare-Start-up immatics NV, dessen anstehende Phase III Studie und eine A...

Weiterlesen

Hot Seat: Marvin Hodde | Hydrogenea

19.09.2024

Grüner Wasserstoff ist ohne Frage ein Energieträger, der einen entscheidenden Beitrag zur nachhaltigen Transformation...

Weiterlesen